中国医药
中國醫藥
중국의약
China Medicine
2015年
11期
1593-1595
,共3页
石明%唐友勇%杨中卫%李威%王正艳%袁美春
石明%唐友勇%楊中衛%李威%王正豔%袁美春
석명%당우용%양중위%리위%왕정염%원미춘
支气管扩张症%支气管哮喘%布地奈德福莫特罗%肺功能%生活质量
支氣管擴張癥%支氣管哮喘%佈地奈德福莫特囉%肺功能%生活質量
지기관확장증%지기관효천%포지내덕복막특라%폐공능%생활질량
Bronchiectasis%Bronchial asthma%Budesonide formoterol%Lung function%Life quality
目的 探讨布地奈德福莫特罗对支气管扩张症合并支气管哮喘患者肺功能及生活质量的影响.方法 选择2012年6月至2015年1月于湖北医药学院附属东风医院就诊的支气管扩张症合并支气管哮喘患者98例,根据随机数字表法分为观察组和对照组,各49例.对照组给予布地奈德吸入治疗,观察组给予布地奈德福莫特罗吸入治疗,2组均治疗15 d.比较2组患者治疗前后肺功能、炎性因子水平、生活质量评分以及不良反应发生情况.结果 治疗15 d后,观察组第1秒用力呼气容积和用力肺活量明显高于治疗前和对照组同时点[(2.3 ±0.5)L比(1.9±0.5)、(2.1±0.7)L,(3.5±0.9)L比(3.1±0.9)、(3.2±0.5)L],白细胞介素4、肿瘤坏死因子α、生活质量评分明显低于治疗前和对照组同时点[(5.4±2.1) ng/L比(27.3±2.4)、(9.1±1.9)ng/L,(20±14) ng/L比(124±14)、(50±14) ng/L,(36±5)分比(49±5)、(45±5)分],差异均有统计学意义(均P ＜0.05).观察组治疗过程中出现声音嘶哑2例、口干1例、心慌1例;对照组出现声音嘶哑1例、口干2例,2组对症处理后均好转,2组不良反应发生率比较[8.2％(4/49)比6.1％ (3/49)],差异无统计学意义(P＞0.05).结论 布地奈德福莫特罗能明显改善支气管扩张症合并支气管哮喘患者的气道炎症、肺部功能和生活质量,安全性、可靠性较好.
目的 探討佈地奈德福莫特囉對支氣管擴張癥閤併支氣管哮喘患者肺功能及生活質量的影響.方法 選擇2012年6月至2015年1月于湖北醫藥學院附屬東風醫院就診的支氣管擴張癥閤併支氣管哮喘患者98例,根據隨機數字錶法分為觀察組和對照組,各49例.對照組給予佈地奈德吸入治療,觀察組給予佈地奈德福莫特囉吸入治療,2組均治療15 d.比較2組患者治療前後肺功能、炎性因子水平、生活質量評分以及不良反應髮生情況.結果 治療15 d後,觀察組第1秒用力呼氣容積和用力肺活量明顯高于治療前和對照組同時點[(2.3 ±0.5)L比(1.9±0.5)、(2.1±0.7)L,(3.5±0.9)L比(3.1±0.9)、(3.2±0.5)L],白細胞介素4、腫瘤壞死因子α、生活質量評分明顯低于治療前和對照組同時點[(5.4±2.1) ng/L比(27.3±2.4)、(9.1±1.9)ng/L,(20±14) ng/L比(124±14)、(50±14) ng/L,(36±5)分比(49±5)、(45±5)分],差異均有統計學意義(均P ＜0.05).觀察組治療過程中齣現聲音嘶啞2例、口榦1例、心慌1例;對照組齣現聲音嘶啞1例、口榦2例,2組對癥處理後均好轉,2組不良反應髮生率比較[8.2％(4/49)比6.1％ (3/49)],差異無統計學意義(P＞0.05).結論 佈地奈德福莫特囉能明顯改善支氣管擴張癥閤併支氣管哮喘患者的氣道炎癥、肺部功能和生活質量,安全性、可靠性較好.
목적 탐토포지내덕복막특라대지기관확장증합병지기관효천환자폐공능급생활질량적영향.방법 선택2012년6월지2015년1월우호북의약학원부속동풍의원취진적지기관확장증합병지기관효천환자98례,근거수궤수자표법분위관찰조화대조조,각49례.대조조급여포지내덕흡입치료,관찰조급여포지내덕복막특라흡입치료,2조균치료15 d.비교2조환자치료전후폐공능、염성인자수평、생활질량평분이급불량반응발생정황.결과 치료15 d후,관찰조제1초용력호기용적화용력폐활량명현고우치료전화대조조동시점[(2.3 ±0.5)L비(1.9±0.5)、(2.1±0.7)L,(3.5±0.9)L비(3.1±0.9)、(3.2±0.5)L],백세포개소4、종류배사인자α、생활질량평분명현저우치료전화대조조동시점[(5.4±2.1) ng/L비(27.3±2.4)、(9.1±1.9)ng/L,(20±14) ng/L비(124±14)、(50±14) ng/L,(36±5)분비(49±5)、(45±5)분],차이균유통계학의의(균P ＜0.05).관찰조치료과정중출현성음시아2례、구간1례、심황1례;대조조출현성음시아1례、구간2례,2조대증처리후균호전,2조불량반응발생솔비교[8.2％(4/49)비6.1％ (3/49)],차이무통계학의의(P＞0.05).결론 포지내덕복막특라능명현개선지기관확장증합병지기관효천환자적기도염증、폐부공능화생활질량,안전성、가고성교호.
Objective To explore the effect of budesonide formoterol on lung function and quality of life in patients with bronchiectasis complicated with bronchial asthma.Methods Totally 98 patients with bronchiectasis complicated with bronchial asthma from June 2012 to January 2015 were randomly divided into observation group (49 cases) given inhalation of budesonide formoterol, and control group (49 cases) given inhalation of budesonide;the treatment was lasted for 15 d.The lung function, levels of inflammatory cytokines, score of life quality and adverse reactions before and after treatment were compared between the two groups.Results After treatment, the forced expiratory volume in one second and forced vital capacity in observation group were obviously higher than those before treatment and those in control group at the same time point [(2.3 ± 0.5) L vs (1.9 ± 0.5), (2.1 ±0.7) L, (3.5 ±0.9) L vs (3.1 ±0.9), (3.2 ±0.5) L].The serum interleukin-4, tumor necrosis factor-a, score of life quality in observation group after treatment were significantly lower than those before treatment and those in control group at the same time points [(5.4 ± 2.1) ng/L vs (27.3 ± 2.4), (9.1 ± 1.9) ng/L, (20±14) ng/Lvs (124±14), (50±14) ng/L;(36±5) scoresvs (49±5), (45±5) scores] (P ＜ 0.05).During treatment, 2 patients had hoarse voice, 1 patient had dry mouth and 1 patients had palpitation in observation group;1 patients had hoarse voice, 2 patient had dry mouth in control group;all the patients recovered after symptomatic treatment;the incidence of adverse reactions had no significant difference between observation group and control group [8.2％ (4/49) vs 6.1％ (3/49)] (P ＞0.05).Conclusion Budesonide formoterol can obviously improve the lung function, airway inflammation and life quality in bronchiectasis patients complicated with bronchial asthma.
